Generation and Characterization of a Novel Small Biologic Alternative to Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Antibodies, DS-9001a, Albumin Binding Domain-Fused Anticalin Protein

The Journal of Pharmacology and Experimental Therapeutics
Yusuke MasudaTomohiro Nishizawa

Abstract

Since it was recently reported that an antibody for proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces the risk of cardiovascular events in a clinical context, PCSK9 inhibition is thought to be an attractive therapy for dyslipidemia. In the present study, we created a novel small biologic alternative to PCSK9 antibodies called DS-9001a, comprising an albumin binding domain fused to an artificial lipocalin mutein (ABD-fused Anticalin protein), which can be produced by a microbial production system. DS-9001a strongly interfered with PCSK9 binding to low-density-lipoprotein receptor (LDL-R) and PCSK9-mediated degradation of LDL-R. In cynomolgus monkeys, single DS-9001a administration significantly reduced the serum LDL-C level up to 21 days (62.4% reduction at the maximum). Moreover, DS-9001a reduced plasma non-high-density-lipoprotein cholesterol and oxidized LDL levels, and their further reductions were observed when atorvastatin and DS-9001a were administered in combination in human cholesteryl ester transfer protein/ApoB double transgenic mice. Additionally, their reductions on the combination of atorvastatin and DS-9001a were more pronounced than those on the combination of atorvastatin and anacetrapib. Besides its...Continue Reading

References

Jul 1, 1996·The Annals of Pharmacotherapy·J T JørgensenL Musaeus
Aug 22, 1997·The Journal of Biological Chemistry·D Steinberg
Apr 4, 1998·The American Journal of Cardiology·H N Ginsberg
Jun 8, 2002·Advanced Drug Delivery Reviews·M J RobertsJ M Harris
Jul 5, 2002·The Journal of Biological Chemistry·Tetsuya ShimizugawaHidehiko Furukawa
Oct 22, 2002·The Journal of Pharmacology and Experimental Therapeutics·Blaire L OsbornCynthia Sung
Apr 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Shirya RashidJay D Horton
Mar 31, 2006·Human Molecular Genetics·Jamie CameronTrond P Leren
Sep 12, 2007·Journal of Pharmaceutical Sciences·Padma Malyala, Manmohan Singh
Feb 21, 2009·Journal of the American Chemical Society·Hyun Jin KimArne Skerra
May 16, 2009·Proceedings of the National Academy of Sciences of the United States of America·Joyce C Y ChanSimon M Jackson
Dec 17, 2009·Methods in Molecular Biology·Sampath ParthasarathyNalini Santanam
Feb 23, 2012·International Journal of Biological Sciences·Liwen ZhangAyesha Sitlani
Nov 29, 2013·Journal of Pharmaceutical Sciences·Benjamin Wu, Yu-Nien Sun
Apr 29, 2014·European Journal of Pharmacology·Thomas P RoddyDouglas G Johns
Jun 12, 2014·The Journal of Pharmacology and Experimental Therapeutics·Tracy MitchellRex A Parker
Jun 25, 2014·Nature Reviews. Cardiology·Razvan T Dadu, Christie M Ballantyne
May 12, 2015·The Journal of Clinical Investigation·John S MillarDaniel J Rader
Jun 16, 2015·BioMed Research International·Jesús ZurdoIngmarie Höidén-Guthenberg
Sep 6, 2015·Journal of Lipid Research·Sam J L van der TuinYanan Wang
Sep 18, 2015·Journal of Lipid Research·Philip J BarterKerry-Anne Rye
Mar 18, 2017·The New England Journal of Medicine·Marc S SabatineUNKNOWN FOURIER Steering Committee and Investigators
Jul 4, 2017·Nature Reviews. Nephrology·David Preiss, Colin Baigent

❮ Previous
Next ❯

Citations

May 12, 2018·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Christine Rothe, Arne Skerra
Jan 11, 2019·Cardiovascular Research·Nabil G SeidahGiuseppe Danilo Norata
Mar 21, 2019·Future Medicinal Chemistry·Antonio Lavecchia, Carmen Cerchia
Jul 28, 2020·Expert Opinion on Biological Therapy·Amir Mohammad MalvandiAlberico Luigi Catapano
Jan 10, 2020·Annual Review of Pharmacology and Toxicology·Michaela Gebauer, Arne Skerra
Jan 24, 2019·Clinical Science·Natalie C WardGerald F Watts
Oct 20, 2020·Expert Opinion on Biological Therapy·Friedrich-Christian DeuschleArne Skerra
Jan 22, 2020·ACS Chemical Biology·Daniel J BurdickDaniel Kirchhofer

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.